Search - tctmd.com

Displaying 1 - 20 of 189

Sort: Relevancy | Date

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Caitlin E. Cox

November 08, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Daily News

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

Todd Neale

September 18, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Daily News

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Michael O'Riordan

July 18, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

No Clear Risk of Dementia After TIA: Framingham Heart Study

L.A. McKeown

July 10, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

Advertisement

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Year in Review: Top Prevention Stories of 2025

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Risk Factors Present in Nearly All Patients Who Develop CVD

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

No Clear Risk of Dementia After TIA: Framingham Heart Study

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content